Nuwellis initiates its outpatient heart failure strategy using aquadex ultrafiltration therapy

Minneapolis, july 12, 2022 (globe newswire) -- nuwellis, inc. (nasdaq: nuwe), a commercial-stage company focused on improving the quality of life for people with fluid overload, today announced key takeaways from its recent physician-led webinar discussing the benefits of treating fluid overloaded heart failure (hf) patients with aquadex® ultrafiltration (uf) in the outpatient setting – the first step toward commercializing this opportunity.
NUWE Ratings Summary
NUWE Quant Ranking